A phase I, prospective study of Anti-NY ESO 1 CAR-T cell therapy for failed recurrent sarcoma
Latest Information Update: 17 Aug 2020
At a glance
- Drugs Anti-NY-ESO-1 CAR T cell therapy-Eutilex (Primary)
- Indications Sarcoma
- Focus Adverse reactions
- 17 Aug 2020 New trial record